The layoffs will affect employees in research, clinical development and administrative roles.
In addition, Dynavac CEO Eddie Gray will step down from his role Aug. 1 as part of the restructuring effort.
The plan comes as the biotech works to shift its focus and resources from immuno-oncology and to vaccines, including its first commercial product, which is a hepatitis B vaccine.
Read the full report here.
More articles on pharmacy:
How hospitals can better align the pharmacy to achieve its strategic goals
Google sister-company Verily partners with big pharma for clinical trials
Merck’s Keytruda fails late-stage trial as standalone treatment for breast cancer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.